Donald Trump hinted that he could have an “October surprise” in a SARS-CoV-2 vaccine. That isn’t going to happen. The closest is Pfizer’s announcement that it may apply for emergency authorization for its vaccine before the end of November. But, of course, that’s after the election.
The pharmaceutical companies, fortunately, are more interested in preserving their credibility than in currying Trump’s favor. Perhaps they have calculated that Trump is unlikely to win a second term.
ProPublica has a long article on how vaccines are approved. If you want the whole story, check it out. Here’s a tl;dr to provide more of a checklist.Read More